KP-301 AAV clinical initiation
Mirador licensed KP-301, a long-acting sweeping anti-C5a antibody, in July 2026 with an initial focus on ANCA-associated vasculitis. The license is distinct from dosing patients in that indication.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Indication-development candidate — trial date unconfirmed
Company context
Company-authored LinkedIn About explicitly states Type: Privately Held and links miradortx.com. Opened and checked October 31, 2026. This is an undated company self-report, not independent registry proof. The Series B announcement is context only, not the ownership evidence.
Potential outcome market
Will a participant with ANCA-associated vasculitis receive KP-301 in an authorized Mirador-sponsored trial by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.